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Abstract
Traditional real options models regard the idiosyncratic risk of a project as
the main value driver. Beyond the specific risks embedded in the project, i.e.,
both its technical and idiosyncratic risk, our model captures the interactions
among different market, economic and social forces and their impact on R&D
project valuation. Using Fourier series, our model aggregates external forces
that play relevant roles in the process that determines the cash flow structure.
Consequently, the posited model provides managers and policy makers with a
powerful yet flexible tool to stress test several economic scenarios under which
the project could develop. In a practical case, we apply our novel model and
methodology to the valuation of a pharmaceutical R&D project and examine
the impact of external forces on the optimal time to launch the project. The
real options approach also allows for the possibility of optimally abandoning a
project before completion whenever the investment cost exceeds the expected
net cash flow stream after considering the impact of market conditions.
JEL classification: G12, G17, G32, C22, C63.
Keywords: Real options, R&D, Economic conditions, Fourier series,
Pharmaceutical industry, Stress test
Email addresses: Marie.Lambert@uliege.be (Marie Lambert), manuel.moreno@uclm.es




Productivity, technology diffusion and innovation driven by R&D have been
of major interest for academics and policy makers since the early seventies. How-
ever, research progress has been made since the seminal framework of Griliches
(1979), which assumes a linear relationship between R&D and firm productivity.5
Kancs and Siliverstovs (2016), for instance, report a non-linear relationship be-
tween productivity growth and R&D expenses. In a recent contribution, Ugur
et al. (2016) investigate the firm-level and social impact of R&D and identify
conditions for knowledge spillovers. Given these potential economic and social
repercussions, R&D spending remains an issue of the utmost relevance for prac-10
titioners, academics and policy makers. Specifically, Brautzsch et al. (2015)
study the macroeconomic effects of R&D subsidies during the economic crisis
of 2008-2009 in Germany, while Gonza´lez and Pazo´ (2008) analyze the effects
of public financing on private R&D investment.
R&D decision making relies heavily on the accurate valuation of the project.15
In this regard, a widely accepted valuation method is the real options approach.
Option-like features allow the incorporation of considerable flexibility into the
valuation process, i.e., the project can be optimally abandoned or delayed. In
contrast to the discounted cash flow (DCF) method, the real options approach
successfully captures the value of the managerial decision-making process.20
An uninvestigated issue in R&D valuation is the extent to which such valua-
tion is affected by external economic conditions and the optimal time to launch
a project. Indeed, both methods fail to incorporate the contributions of external
forces, such as market conditions, economic forces, public opinion, and political
influence. Recently, several examples have demonstrated the impact of external25
conditions on the value of an R&D project. For instance, the 2014 Ebola out-
break revealed the lack of resources and effort allocated by the pharmaceutical
industry to combating this virus while it was limited to or contained within
African borders. The pharmaceutical industry’s interest only increased when
the virus crossed European and American borders and “opened a new market”.30
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The aim of this paper is to provide a comprehensive methodology for valuing
R&D projects because they are subject not only to technical uncertainty but
also to external factors that contribute to the valuation process. This enables
the use of stress testing around the optimal market launch based on economic
conditions.35
To address the above-mentioned gap in R&D valuation research, we propose
a model that is able to capture the interactions among different market, eco-
nomic, and external forces. Fourier series are a simple and flexible mathematical
tool to represent a function as the sum of a set of simple sines and cosines. Such
a representation allows us to aggregate all the forces that impact the generation40
of a project’s cash flows.
The posited model allows managers and policy makers to stress test several
scenarios under which a project may develop. Hence, it can be used to depict
any extreme economic and social situation and properly value an R&D project
targeting such a market. Furthermore, since some projects are developed with45
contributions from the public sector —see, for instance, Cockburn and Hen-
derson (2000)—this model can be implemented to determine the appropriate
amount of taxpayer money to allocate to a specific project, to analyze strategic
interactions, or to incorporate the factors affecting R&D spending. Recently,
Hammadou et al. (2014) analyze the determinants of public spending in R&D50
accounting for several factors such as international context, GDP, or openness.
Note that public opinion is a strong force than can substantially affect the value
of a project. For instance, the pharmaceutical industry has divided public opin-
ion in several controversial areas, such as animal testing, drug prices, the lack of
interest in research on certain diseases, and public funding. However, industries55
such as nanotechnology benefit from remarkably positive reputation based on
their potential benefits and applications in transportation, energy, and environ-
mental science, among others. Hence, we might expect external forces to make
different contributions during the R&D processes of pharmaceutical and nan-
otechnology projects. In this paper, we claim that these effects can be modeled60
by using appropriate terms in the Fourier expansion.
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The R&D process is extremely complex, and the interactions of external fac-
tors depend heavily on the industry and project under consideration. However,
the approach proposed in this paper can accommodate very specific situations.
Our practical case covers a pharmaceutical R&D project; however, the model65
and methodology used can be easily extrapolated to any industry, for instance,
projects in the car industry.
The remainder of this paper is structured as follows: Section 2 is devoted to
the literature review. Section 3 presents the valuation model, technicalities, and
implications. In Section 4, we perform a stress test analysis to determine the70
impact of exogenous forces and the optimal launching of a pharmaceutical R&D
project. Finally, Section 5 concludes by citing the contribution of our model to
the literature and its implications for practitioners and policy makers.
2. Literature review
The extant literature on the use of real options models for valuing R&D75
projects treats the successful completion of the R&D phase as exogenous vari-
able. Some examples follow. Majd and Pindyck (1987) use a geometric Brow-
nian motion to model the evolution of a project’s market value after market
launch and conditional on a successful R&D stage. The authors show that the
arrival of new information might lead the firm to depart from its original spend-80
ing plan. Therefore, traditional DCF methods, as they do not capture man-
agerial decision flexibility, are inadequate for properly valuing projects where
spending decisions and cash outlays occur sequentially over time. Assuming
that the gross project value follows a geometric Brownian motion, Trigeorgis
(1993) analyzes the valuation of flexible capital budgeting projects as a col-85
lection of real options and investigates the impact of the interactions among
these options. Pennings and Sereno (2011) value a compound R&D option
while assuming a geometric Brownian motion process for the underlying value
of the project and a Poisson random variable for the technical failure probability.
Berk et al. (2004) model the cash flows generated by a single R&D investment90
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project using two distinct stochastic processes. One process models any possible
catastrophic event, and the other models the conditional cash flows the project
would have produced if it had been completed. The authors assume that the
cash flows last forever, thereby allowing them to value the completed project
using a continuously compounded version of the growing perpetuity formula.95
Finally, Schwartz (2004) implements a simulation approach for valuing patents
and patent-protected R&D projects. He assumes two stochastic differential pro-
cesses, one for the cost of completion and another for the cash flows generated
from the project, and the probability of a technical failure is introduced as a
Poisson probability.100
In our model, we consider the net cash flow as the underlying variable. In
this sense, our approach is closer to the work of Berk et al. (2004) and Schwartz
(2004). Similar to the literature, we will use a Poisson process to model technical
risk and start modeling a project’s cash flows under the assumption of a market
launch. As in Alexander et al. (2012), however, we assume that the net cash105
flow of a successful project is given by an arithmetic Brownian motion process.
This captures the fact that the underlying variable could yield a negative cash
flow stream if one considers the production and marketing costs.
An important feature of R&D projects is their uncertainty related to the
cost of completion. For an in-depth examination of this topic, see for instance,110
DiMasi et al. (1991) and Hansen (1979). In particular, DiMasi et al. (2003)
perform a thorough study of the R&D costs for 68 randomly selected new drugs
produced by 10 different pharmaceutical companies and estimate the cost of
pharmaceutical innovation. Pindyck (1993) also studies investment decisions
when projects are subject to two different sources of uncertainty, technical un-115
certainty and cost uncertainty. Although the sources and amounts of cost uncer-
tainty vary greatly across projects, cost uncertainty is shown to have a deeper
impact than technical uncertainty on the value of the investment opportunity.
Different sources of uncertainty might also play a key role in R&D decision
making; for instance, Garcia-Quevedo et al. (2014) show that uncertainty over120
product/service demand has a substantial impact on the amount of investment
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and the likelihood of engaging in R&D projects.
Other relevant studies of real options valuation include Childs and Triantis
(1999), who examine dynamic R&D investment policies and the valuation of
R&D programs in a contingent claim framework. The authors study interac-125
tions among multiple R&D project cash flows and analyze how the firm alters
its funding policy over time. Smith and Nau (1995) compare the classical DCF
approach (or risk-adjusted discount-rate analysis), options pricing analysis, and
decision tree analysis approaches to valuing risky projects. Posner and Zuck-
erman (1990) determine the optimal time to abandon an R&D project under130
the assumption of a stochastic process for expenditures. McDonald and Siegel
(1986) compare the optimal timing of investments and assume a geometric Brow-
nian motion for the future net cash flows (with and without jumps) and another
geometric Brownian process for the cost of completion. Brown et al. (2017) an-
alyze the financial market rules and the effectiveness of domestic policies to135
promote R&D.
The literature summarized above does not, however, provide a real options
framework able to capture a project’s flexibility in terms of abandon options
and the impact of economic conditions on the project’s specific risks. The model
built in Section 3 allows us to perform a stress test analysis with the objective140
of timing the launch of the project after taking into account the impact of ex-
ternal forces, while considering both technical and idiosyncratic sources of risk.
McDonald and Siegel (1986) and Posner and Zuckerman (1990) already consider
the optimal timing of investments. However, their framework does not unveil
the impact of exogenous forces. To account for these external forces, we assume145
that the net cash flow of a successful project is given by an arithmetic Brow-
nian motion process plus a time-dependent component depicted by a Fourier
series. For illustrative purposes, this time-dependent component captures the
interaction between the business and volatility cycles.
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3. R&D valuation model150
It is well established in the literature—see, for instance, Brealey and My-
ers (2000)—that an R&D project faces two major sources of risk, economic
and technical. Technical or technological risk takes into account the inherent
uncertainty over the successful completion of each stage during the drug devel-
opment phase; for instance, an extreme side effect during clinical testing could155
lead to failure. By contrast, economic risk addresses market uncertainty around
sales volumes, pricing levels, and market competitors. One part of this risk is
idiosyncratic in nature, and the other part is instead systematic and can be
related to external economic factors such as interest rates, inflation rates, and
growth rates. To effectively value research and development projects, we need160
to properly capture both sources of risk at the appropriate time.
3.1. Technical uncertainty
Technical or technological risk is the primary source of uncertainty during
the development process. For instance, regarding pharmaceutical R&D projects,
most drugs in the preclinical and clinical stages do not obtain the regulatory165
authority’s approval. Since each stage must be preceded by the successful com-
pletion of the previous one, the failure of one stage leads to overall project
termination. However, we assume that once the project successfully passes ev-
ery test and stage of the R&D process and finally achieves regulatory approval,
technical risk virtually vanishes. In this regard, the use of a Poisson process to170
model technical or technological risk is widespread—see, for instance, Pennings
and Sereno (2011) and Schwartz (2004). The Poisson probability mass function





where λ > 0 is the Poisson parameter, and k = 0, 1, 2, ...,∞ defines the number
of events. Generalizing k = 1, 2, ...,∞ as any possible technical event and k = 0175
as no technical event, we have
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Probability of success = e−λ (2)





= 1− e−λ (3)
Hence, the expected project value conditional on technical risk is given as
E [Vt|Technical Risk] = Vt(k = 0) · e






• Vt(k = 0) is the value of a successful project
• Vt(k = 1, 2, ...,∞) is the residual value of a failing project
Although a failed project might still increase a company’s stock of knowl-180
edge, it is common to assume that the outcome of a failure is a worthless
project. Under this assumption, technical risk translates to a premium over
the risk-free rate. During the development process, the discount factor is given
by e−rdt = e−(r+λ)t, where λ represents the annual rate of failure, and r is the
risk-free rate. Note that, as stated above, technical risk vanishes after the reg-185
ulatory authority’s approval; hence, this premium is only valid during the drug
development phase.
3.2. Idiosyncratic risk
It is common to model the evolution of a project or the evolution of its cash
flow as a stochastic differential equation190
dCt = µ(C, t)dt + σ(C, t)dW (5)
where the process can take the form of a geometric Brownian motion, an arith-
metic Brownian motion, or an Ornstein-Uhlenbeck process. We can use a more
realistic and sophisticated framework, such as that proposed by Schwartz (2004),
in which both the cash flow and the cost of completion are modeled by stochas-
tic differential equations. In this paper, we consider the evolution of the net195
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cash flow over time. The net cash flow stream takes into consideration the pro-
duction and marketing costs; consequently, it could yield a negative rate. Thus,
an arithmetic Brownian motion is a suitable representation of the underlying
process.
As long as we consider only one stochastic factor, all these models have a200
single source of uncertainty that comes from a random walk weighted by σ(C, t),
that is, the diffusion term.1 It seems fairly obvious that a simple diffusion
model cannot account for a realistic variety of forces affecting the project’s
market phase. In particular, none of these models can properly account for
seasonal components. For instance, seasonality plays a primary role in influenza205
outbreaks. These models also do not consider the effects of the business cycle or
other relevant forces. At this point, it is worth considering whether such models
are oversimplifications and identifying which forces really make an impact in
terms of project valuation. The next subsection addresses this issue. Of course,
there is no one right answer, as each project must be analyzed to determine210
the appropriate set of relevant forces. However, it seems fair to conclude that a
simple diffusion model is a naive simplification of the market structure.
3.3. External conditions and forces
In this sub-section, we introduce the contributions of external factors and
conditions affecting the valuation process defining the cash flow structure of215
a successful project, which gives rise to the project’s abandon option. These
are economic factors (both macro- and microeconomic) driving the systematic
component of cash in- and outflows. Note that we intentionally use the phrase
“successful project” because we have divided projects into two major phases,
the R&D phase and the market phase. During the R&D phase, technical risk is220
the dominant source of uncertainty, which vanishes once the project successfully
completes each stage in the development process and finally achieves approval.
1The options pricing literature has been very fruitful in terms of models with two and even
three stochastic factors — see for instance, Chen (1996) —.
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Projects reaching the market phase are successful projects. Once the project
reaches the market phase, several forces play a significant role in what we call
the external force contribution; however, it is important to remember that only225
a successful project will be affected by the contributions of these external forces.
We consider the net cash flow stream Ct of a successful project given by a
latent variable Yt and depicted by an arithmetic Brownian motion process and
a time-dependent component described by a Fourier series, that is
Ct = f(t) + Yt (6)
dYt = µdt+ σdWt (7)
f(t) = Fourier Series (8)
where {(µ, σ) ∈ R}. Note that in applying Ito’s lemma to equation [6], the net230









In this framework, the solution of the underlying process and the net cash














where WQt is a standard Wiener process under the risk-neutral measure P
Q.
As in Schwartz (2004), the cash flow stream starts at market launch. Before235
this stage, the process describes the net cash flow that the project would have
produced were it successfully completed. Once the project is launched in the
market, its value depends exclusively on the net cash flow generated. Hence,
using the Merton (1973) no-arbitrage technique, the project value V (Ct, t) must
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− rV = 0 (12)
subject to the appropriate terminal condition V (C, T ), where T represents
patent expiration.
The novel component of this model is the ad hoc incorporation of the Fourier
series f(t), which accounts for any economic, market, and specific forces affecting
the project and not captured by the underlying stochastic differential equation.245
The Fourier series represents aggregate forces playing a relevant role in the
process evolution and determining the cash flow structure. Note that the Fourier
series provides a great deal of flexibility, as by Carleson’s theorem, it converges
almost everywhere for an L2 function. Therefore, f(t) allows us to properly
define a scenario where a project will be developed, and such a scenario is250
tailored to the characteristics of each project, the influence of and exposure to
certain forces, and other features. In this regard, we might not have a precise
ex ante projection of such a scenario; for instance, we might know that the
business cycle represents a risk factor, but we might not know how deeply it
affects the cash flow stream. Hence, let us represent economic uncertainty by255
the state vector
Φ(j) with j ∈ N (13)
where each state defines a case scenario depicted by the concrete selection of
terms in the Fourier expansion and represents the aggregate forces. It is im-
portant to stress that a state scenario does not attempt to replicate a precise
future outcome but establishes an alternative future development. Each state260
determines the cash flow structure of a successful project and, consequently, the
managerial decision to cease or continue the project. Thus, the expected patent
value, conditional on a certain economic state, is given as
V
(







with j ∈ N (14)
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where Ct and It represent the net cash flow structure once the project obtains
marketing approval and the investment structure during the R&D phase, re-265
spectively.
Note that the conditional patent value is constrained to the future devel-
opment of each state, which is, of course, uncertain. Since Φ is defined as a
discrete state vector, an essential piece of the puzzle is the appropriate defini-
tion of its PMF. In this regard, Huchzermeier and Loch (2001) define a one-270
dimensional parameter i to model product performance. The authors claim that
this performance may unexpectedly improve with probability p or deteriorate
with probability (1− p). They generalize the binomial distribution by allowing
both performance improvement and deterioration over N performance states.
We can easily accommodate a similar PMF defining two states in the economic275
state vector, that is, j = 1, 2. However, as stated above, each state represents
aggregate forces acting on the project and is therefore very project specific, so
we will implement a Bayesian approach and assign a prior probability to each
scenario. Note that each state can be defined in several ways; for example,
we can tailor it to our expectations or define it based on analyst expectations.280










where pj represents the probability that the state Φ
(j) is real. Hence, under this














4. Stress test and optimal market launch for pharmaceutical R&D
projects285
In this section, we focus on pharmaceutical R&D projects; however, the
methodology can be easily extrapolated to any industry.
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Developing a new medicine is a challenging endeavor, and the chances of
success are extremely low. There are several complex forces, both economic
and technical (idiosyncratic and systematic), governing the drug development290
process that are not entirely understood. The first obstacle arises during the
early discovery stage when the company has to assign the appropriate amounts
of financial and scientific resources. Although the total cost of developing a new
medicine varies, it heavily depends on the type of compound, the drug under
development, and the likelihood of failure. In terms of time to completion, a295
pharmaceutical R&D process can take, roughly speaking, between ten and fif-
teen years from the early-stage discovery of a new compound to the marketing
approval and market launch of a product. Again, this timeline heavily depends
on the drug or treatment. For some innovative drugs or treatments, both cost
and time to completion are significant sources of uncertainty, and they consti-300
tute the cost of innovation. However, many “new” medicines or treatments are
improvements on existing drugs. In this case, the cost and time to completion
are quite standardized, and although there is some uncertainty, the financial
and technological R&D costs are considerably lower.
Consider, for instance, a pharmaceutical R&D project to develop a new305
drug. The very nature of such a project and the potential impact on human
health make the pharmaceutical industry unique and quite risky. There are
several strict and well-regulated stages, spanning early-stage drug discovery to
the marketing approval and market launch of a product. Fig. 1 illustrates a
schedule for a generic pharmaceutical R&D project.310
Figure 1: This figure presents a general pharmaceutical process for the development of
a new drug.
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The overall project life can be divided into two major phases: first, the
R&D phase and, second, the market phase. During the early stage of the R&D
phase, a new compound, which may be developed into a marketable drug, is
either discovered or designed. Once the compound is successfully identified as
a potential drug and synthesized, the project moves to the next stage. Dur-315
ing preclinical and clinical development, the drug must successfully complete a
number of well-regulated stages. First, the preclinical stage covers laboratory
and animal testing, and it is normally during this stage when the company ap-
plies for a patent. If and only if the drug successfully completes the preclinical
stage does it proceed to the clinical stage, which can be divided into clinical320
phases I, II, and III. During clinical phase I, the drug or treatment is tested on
a small group of healthy volunteers to determine the safe dosage, evaluate its
safety, and identify possible side effects and toxicity. During clinical phase II,
the drug or treatment is tested on a relatively large group of subjects (100-300)
aﬄicted by the condition that the drug is intended to treat, with the objective325
of further evaluating its safety and efficacy. Finally, clinical phase III consists
of large-scale trials, usually with a few thousand subjects, to confirm the safety
and efficacy of the drug or treatment and to continue to monitor for possible
side effects. The final stage of the R&D phase is marketing approval. Once
again, if and only if the drug successfully completes each preceding stage does330
the regulatory authority decide whether the drug is approved for patient use.
If marketing approval is granted, the project moves to the market phase, where
an appropriate marketing strategy should be established. Finally, the product
is launched in the market.
Over the life of the patent, the company is entitled to a set of exclusive rights335
protecting the project from market competition for a limited time. However,
market competition is not the only force that jeopardizes the successful evolution
of a project.
Economic conditions not only affect the number of investment opportunities
available in the pharmaceutical industry but also play a key role in the cash-340
flow generation of a successful R&D project (i.e., with no technical risk). This
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section is devoted to stress testing the impact of some economic forces on the
overall project value and to determining the best timing for launching a project
based on the interactions among these forces.
4.1. Economic forces345
A vast number of economic variables can potentially affect an R&D project.
For the sake of simplicity, in this paper, we analyze two major forces: i) the
business cycle, defined as the cyclical movement of GDP around its long-term
trend, and ii) the VIX index, which is a forward-looking measure of market
volatility affecting the option market. It is used as a benchmark for the uncer-350
tainty governing market conditions. The objective is not to be exhaustive but
to show that our framework allows us to take external forces into account.
i) Business cycle
The first variable under consideration is the business cycle, i.e., the cyclical
movement of GDP around its long-term trend. The relationship between355
R&D and the business cycle and economic growth has been intensively
studied in the academic literature—see, for instance, Pintea and Thompson
(2007). In this respect, the first step is to disentangle the cyclical behavior
from the long-term trend. To do so, we use a standard Hodrick-Prescott
(Hodrick and Prescott, 1997) filter, the most commonly used tool for this360
task. We also perform a spectral analysis of the cyclical component of GDP
using nonparametric estimates of the population spectrum, as in Hamilton
(1994). The data set includes 278 quarterly GDP observations ranging from
January 1947 to April 2016 obtained from the Federal Reserve Bank of St.






















Figure 2: This figure presents the cyclical component of GDP and its power spectral
density.
The spectral analysis reveals a peak at a frequency of 0.1871Hz, representing
a cyclical period of 5.35 years, which is consistent with similar studies—see,
for instance, Groth et al.
ii) Market volatility370
The second variable under consideration is market volatility. Here, we use
318 monthly observations of the VIX index from January 1990 to June
2016 downloaded from the CBOE web page. We apply the same procedure
used for the GDP time series; that is, a Hodrick-Prescott filter disentangles
the long-term trend from the cyclical component, and then, we perform a375
spectral analysis using nonparametric estimates of the population spectrum.


















Figure 3: This figure presents the cyclical component of the VIX index and its power
spectral density.
The spectral analysis reveals two dominating peaks representing periods of
1.4 and 3.8 years. Interestingly, in contrast to the GDP time series, the380
long-term component of the VIX series also exhibits cyclical behavior but
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Figure 4: This figure presents the long-term fluctuation of the VIX index time series
and its power spectral density.
Indeed, we can observe a peak at a rather short frequency (0.0755Hz),
representing a cycle of 13.25 years.385
Note that the parameters included in each term of the Fourier expansion and
defining the behavior of the external economic forces, and hence of each factor,
are the frequency (f) and phase (φ) parameters. The amplitude parameter
defines the intensity of such a force or cycle over the net cash flow stream. This
constitutes a project-dependent parameter.390
4.2. Stress test analysis
Launching a project involves the decision of whether to launch it (with the
embedded option to abandon) based on the technical and market risks involved
and the choice of the optimal launch time. Timing the launch of a project
corresponds to an option to delay. The objective of the stress test analysis is to395
jointly determine the optimal launch time and the impact of the option to delay
on project valuation. Hence, we will simulate different scenarios for the phase
parameter and estimate the change in the project value and the risk of failure
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if the project is launched at different phases of each cycle under consideration.
For instance, we will examine the impact of launching the project at the peak400
or the bottom of the business cycle. Note that we do not intend to price a
specific project but rather to identify the optimal launch time; hence, we will
use average market parameters for a generic R&D project, as described below.
Let us assume that the research team has already identified a compound
that may be used to engineer a new medication. At this stage, the board has to405
face the first abandon option, that is, they have to decide whether this project
constitutes a valid investment opportunity and apply for patent protection;
otherwise, they abandon before any further development. They also have to
decide whether to immediately launch the project or postpone it. For this
purpose, we will stress test the launch date and establish the optimal timing410
considering the different stages of the business cycle and the market volatility.
We assume that there is no uncertainty over the time and cost to completion if
the project successfully overcomes every stage of the development process. Note
that most of the investment cost is incurred in developing the drug, and it can
be modeled stochastically following Schwartz (2004). However, for the sake of415
simplicity, we focus on timing the project kick-off rather than on development
issues. The model could be easily extended to incorporate a stochastic process
for the cost and time to completion. According to the Tufts Center for the Study
of Drug Development—see DiMasi et al. (2014)—the total out-of-pocket cost
per approved new compound is approximately 1,400 million (in 2013 dollars),420
although this figure can be heavily dependent on the development phase—see
Archibugi and Bizzarri (2004). Based on this information, Table 1 presents our
scenario for out-of-pocket investment costs and the yearly development phase
schedule.
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Table 1: Development phase schedule. This table presents the work schedule and budget for
the whole development process, including regulatory approval.
Development Preclinical Clinical Clinical Clinical Regulatory
stage testing phase I phase II phase III review
Period 0 1 2 3 4 5 6 7 8 9
Investment 60 60 82 82 196 196 174 174 174 11
4.2.1. Technical uncertainty425
In the previous section, we assume that during the development phase, the
project can either fail or be abandoned. Technical risk accounts for the probabil-
ity of failure for technical or technological reasons during the development phase,
and we have generalized the Poisson distribution to allow for the probabilities
of technical success and failure. According to the “2015 biopharmaceutical re-430
search industry profile” report provided by PhRMA (Pharmaceutical Research
and Manufacturers of America, 2015), the average time needed to develop a drug
is approximately 10 years, and less than 12% of drugs entering clinical trials re-
sult in an approved medicine. Hence, assuming that only 12% of such projects
complete every stage of the development phase and a development period of 10435
years, the annual rate of failure is given as
e−10·λ = 0.12 (17)
λ = 0.2120 (18)
We also assume that a failure results in a worthless project; hence, during
the development process, the discount factor is given by e−rdt = e−(r+0.2120)t,
where r represents the risk-free rate.
4.2.2. Economic and market uncertainty440
The net cash flow stream from sales revenues, marketing and production
cost starts when the medication receives marketing approval and is launched,
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which is expected to occur in period 10. Let us assume that a patent will be
granted 4 years after the application and provides protection for a period of 20
years. When the patent expires, market competition forces sales to virtually445
zero, meaning that, based on the schedule, the company can only benefit from
this project for 14 years starting at market launch. This assumption generates
the boundary condition V (T ) = 0 on equation [12], where T represents the
patent expiration date. In addition, we consider an initial cash flow parameter
C0 in equation [11] of 100 million, while the process volatility σ is fixed at 20450
million.
As for the economic variables, the previous section specifies the characteris-
tics of each economic variable, that is, the frequency and phase parameters of
the GDP and VIX cyclical components and the VIX long-term component. To
initialize the conditions for the amplitude, we measure the impact of each factor455
relative to a benchmark, and based on these results, we will fix each factor’s
amplitude. As a benchmark, we use two well-known pharmaceutical indexes: i)
the S&P 500 Pharmaceutical Index and the ii) NYSE ARCA Pharmaceutical
Index. Both data series run from July 1992 to April 2016. Table 2 provides the
results.460
Table 2: S&P 500 and NYSE Pharmaceutical Index factor analysis. This table presents
the linear relations between the benchmark indexes and the economic factors (p-values in
parentheses). Note that the economic factors are scaled to fit the index boundaries.
S5PHAR Index DRG Index
GDP cyclical component 0.4907 (<0.001) 0.5011 (<0.001)
VIX cyclical component 0.0932 (0.195) 0.0913 (0.192)
VIX long-term component 0.3440 (<0.001) 0.3151 (<0.001)
R2 0.1275 0.1350
In both cases, we observe that the VIX cyclical component, that is, the fac-
tor composed of two periods of 1.4 and 3.8 years, is not statistically significant.
In contrast, both the GDP cyclical and the VIX long-term components have
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significant relationships with the pharmaceutical return indexes. Recall that
the objective here is not to find all possible external factors. The use of phar-465
maceutical indexes aggregates different projects and might hinder the impact of
some interesting external factors. Our objective is to show that our model can
accommodate the impact of any type of external force as part of the valuation.
Hence, for the stress test analysis, we only consider these two factors, and we
fix the amplitude parameter according to these results and the initial cash flow:470
f(t) = 100 {0.4959 cos (1.1753 · t+ φ1) + 0.3296 cos (0.4742 · t+ φ2)} (19)
where each φi; i = 1, 2 defines the phase factor.
Note that the amplitude itself might be a parameter to be modeled and
simulated to perform the stress test. Finally, for the sake of simplicity, we
will use a constant risk-free rate of 1.5%, although the current value is much
lower. Our model can be easily extended to include finer assumptions about the475
underlying parameters.
4.3. Implementation
Having defined and calibrated all the input parameters, we can compute the
value of this project using the following steps. We assume that the underlying
process Ct defines the monthly net cash flow stream. Then, we simulate 100,000480
paths considering a monthly time increment of ∆t = 1/12. The discrete cash
flow at any time t is given by equation [11]. Once the marketing of the product
is approved, the marketing and production costs are included in the net cash
flow process. Therefore, discounting all the discrete cash flows up to market
launch and summing them could yield a negative aggregate value. For that485
reason, an abandon option is considered at market launch, although there is
no further investment in developing the drug. Recall that the probability of a
negative aggregate cash flow at market launch is the consequence of considering
an arithmetic Brownian motion process and the impact of the Fourier component
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on that process; therefore, such a probability tends to decrease as the economic490
state improves. Accordingly, at market launch, the abandon option is given by
V
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where tML and T represent the market launch and patent expiration date, re-
spectively.
The exercise time for the subsequent abandon options is defined on a yearly
basis, and the option is evaluated conditional on not having been previously495
abandoned; therefore, the time increment during the development phase is given
by ∆t∗ = 1. The backward procedure consists of discounting2 the project value
to the exercise time and evaluating the optimal abandon option, that is,
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(21)
The procedure continues rolling back to the present time for those paths
that are not optimally abandoned in previous interactions.500
4.4. Business cycle stress test
In this section, we perform a sensitivity analysis of the project valuation with
regard to the business cycle factor only. In other words, we analyze the impact
of launching the project at different phases. We study the project’s evolution
when launching i) at the peak of the cycle and then entering a recession, that505
is, φ1 = 0; ii) at the trough of the cycle and then entering the recovery phase,
that is, φ1 = pi; and iii) at an intermediate phase, that is, φ1 = pi/2. In this
case, we use the following Fourier expansion:
f(t) = 100 {0.4959 cos (1.1753 · t+ φ1)} (22)
2Note that during the development phase, the discount factor is given by e−rdt = e−(r+λ)t,
where λ represents the annual rate of failure and can be considered a technical or technological
risk premium.
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When considering, 100,000 path simulations and following the above proce-
dure, the expected patent value conditional on each phase in the business cycle510
is given as in Table 3.
Table 3: Conditional expected patent value. Business cycle. This table presents the patent
value conditional on the phase parameter in the business cycle.
Business Cycle Panel
Phase A B
V (t, Ct, It;φ1 = 0) 908.7 (3.2) 604.1 (4.3)
V (t, Ct, It;φ1 = pi) 2553.7 (4.2) 2522.3 (4.4)
V (t, Ct, It;φ1 = pi/2) 1584.4 (3.9) 1486.2 (4.4)
Panel A: With abandon option
Panel B: Without abandon option
We can clearly see that the timing of the launch has a dramatic impact on
project value. Launching the project at the peak of the business cycle and then
entering a recession yields a much lower expected value, roughly 66% lower than
when launching at the trough phase and 43% lower than when launching at an515
intermediate phase. This evidence shows that our model is able to capture the
impact of market conditions or other external forces on the project’s cash flow
generation. This finding has strong managerial implications, as a flexible model
can accommodate any type of situation, evaluate the impact of external factors
and determine the resilience of the project to endogenous risks and external520
economic forces. The timing of project kick-off affects not only the overall
project value but also the value of the embedded abandon option. Table 3
Panel B shows the project value when the abandon option is not considered:
the abandon option has a higher value when the project is launched at the peak
of the phase. Table 4 disaggregates by state and period the number of paths525
optimally abandoned, that is, the number of abandon options exercised. We
have already stated that the first exercise date is at market launch. Since the
net cash flow stream takes into consideration not only the sales revenues but also
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the production and marketing costs, this variable can, and indeed does, become
negative for some paths. Hence, the abandon option may be optimally exercised530
despite there being no further investment in developing the drug at market
launch. As expected, the number of optimally abandoned paths is significantly
higher when the phase factor is φ1 = 0, making the abandon option considerably
more valuable when the project is launched at the beginning of a recession state.
Table 4: Abandon rate. Business cycle. This table presents the number of optimally aban-
doned projects of 100,000 path simulations. In light gray, we have the number of paths
optimally abandoned disaggregated by state and period. In gray, we have the number of
paths optimally abandoned aggregated by period.
Development Preclinical Clinical Clinical Clinical Regulatory Market
stage testing phase I phase II phase III review launch
Period 0 1 2 3 4 5 6 7 8 9 10
Investment 60 60 82 82 196 196 174 174 174 11 0
1625 1225 1323 1026 1850 1451 1031 806 599 27 22272
φ1 = 0
33235 31610 30385 29062 28036 26186 24735 23704 22898 22299 22272
342 237 202 177 299 205 130 109 72 1 1543
φ1 = pi
3317 2975 2738 2536 2359 2060 1855 1725 1616 1544 1543
947 729 735 573 1043 815 528 399 290 18 8092
φ1 = pi/2
14169 13222 12493 11758 11185 10142 9327 8799 8400 8110 8092
4.5. Market volatility stress test535
In this section, we study the effect of market volatility on an R&D project.
In the previous section, we use the VIX as a proxy for market volatility and
find that two short- to medium-term cycles of 1.4 and 3.8 years and a long-
term cycle of 13.25 years. We also analyzed the effects of these factors on two
pharmaceutical indexes and found that only the long-term component outcome540
is significant.
As with the business cycle, we study the project evolution when launching
i) at the peak of the volatility cycle, that is, φ2 = 0; ii) at the trough of the
cycle, that is ,φ2 = pi; and iii) at an intermediate phase, that is, φ2 = pi/2. For
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this study, we use the following Fourier expansion:545
f(t) = 100 {0.3296 cos (0.4742 · t+ φ2)} (23)
Considering 100,000 path simulations, the expected patent value conditional
on each phase in the volatility cycle is given as in Table 5
Table 5: Conditional expected patent value. Volatility cycle. This table presents the patent
value conditional on the phase parameter in the volatility cycle.
Volatility Cycle Panel
Phase A B
V (t, Ct, It;φ2 = 0) 1132.2 (3.5) 914.93 (4.4)
V (t, Ct, It;φ2 = pi) 2248.8 (4.2) 2215.5 (4.4)
V (t, Ct, It;φ2 = pi/2) 1677.5 (3.9) 1588.5 (4.4)
Panel A: With abandon option
Panel B: Without abandon option
We observe similar behavior as in the business cycle analysis: launching the
project at the peak of the volatility cycle yields a lower patent value, roughly
50% lower than launching at the trough phase and 32% lower than launching at550
an intermediate phase. Table 6 disaggregates by state and period the number
of paths optimally abandoned conditional on each phase value. We observe a
higher abandon rate when the project is launched at the peak of the cycle.
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Table 6: Abandon rate. Volatility cycle. This table presents the number of optimally aban-
doned projects of 100,000 path simulations. In light gray, we have the number of paths
optimally abandoned the disaggregated by state and period. In gray, we have the number of
paths optimally abandoned aggregated by period.
Development Preclinical Clinical Clinical Clinical Regulatory Market
stage testing phase I phase II phase III review launch
Period 0 1 2 3 4 5 6 7 8 9 10
Investment 60 60 82 82 196 196 174 174 174 11 0
1357 1029 1110 802 1613 1216 880 718 480 29 16047
φ2 = 0
25281 23924 22895 21785 20983 19370 18154 17274 16556 16076 16047
470 349 382 251 450 337 229 167 144 9 2751
φ2 = pi
5539 5069 4720 4338 4087 3637 3300 3071 2904 2760 2751
926 644 682 499 913 717 456 375 260 14 7060
φ2 = pi/2
12546 11620 10976 10294 9795 8882 8165 7709 7334 7074 7060
The stress test reveals that for both cycles (the business cycle of 5.35 years
and long-term volatility cycle of 13.25 years), the optimal strategy is to launch555
the project at the trough of each cycle. By launching at this point, we achieve
the highest expected patent value and the lowest abandon rate. However, syn-
chronizing both cycles might not be possible, and we still have to determine the
optimal launching time conditional on certain economic conditions.
4.6. Business cycle and market volatility stress test560
In this analysis, we jointly consider the economic forces to understand their
joint effect on the project value, time to launch and abandon option. The Fourier
expansion is given as follows:
f(t) = 100 {0.4959 cos (1.1753 · t+ φ1) + 0.3296 cos (0.4742 · t+ φ2)} (24)
Fig. 5 presents all possible combinations of phases and corresponding patent
values. As previously stated, the best possible combination is launching the565
project when the business and the volatility cycle phase parameters are both
equal to pi, that is, at the trough of both cycles.
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Figure 5: This figure presents the conditional patent value sensitivity considering dif-
ferent combinations of the business and volatility cycle parameters.
Fig. 5 provides the patent value surface at any phase combination. It consti-
tutes a powerful analytical tool to understand the impact of external forces on
the project value. It provides managers with important information for timing570
the introduction of an R&D product to the market.
5. Concluding remarks
Given the social and economic benefits of R&D and the amount at stake
(R&D expenditures amounted to $ 1,143,005 million in 2015 for OECD coun-
tries), any restrictions on public spending should require priority in selecting575
projects and a proper evaluation of their risks and value.
Traditionally, R&D projects have been evaluated following the real options
approach, which relies on one diffusion process to model the idiosyncratic source
of risk and the possibility to abandon the project. The models used in the
literature also allow for the incorporation of the impact of technical risk and580
a stochastic cost of completion. In this paper, we developed a novel valuation
model that accounts for, beyond idiosyncratic and technical risk, the interaction
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of market and economic external forces. The approach allows us to evaluate the
effects of these risk factors on the project value, on the option to abandon and
on the option to delay the project.585
For illustrative purposes, we posit business and volatility cycles as potential
economic risk factors driving the stock return process and the risk premium,
and we consider i) the business cycle as the cyclical movement of GDP around
its long-term trend and ii) the VIX index, which is considered the barometer of
investor sentiment and market volatility.590
To capture these risk factors and account for economic conditions, we intro-
duce a Fourier series into the cash flow generation. This representation enables
us to capture the potential interactions among different market and economic
forces. In this sense, the Fourier series allows us to properly embed an economic
scenario within the project’s cash flow generation. Our model is flexible and can595
accommodate various scenarios by modeling different economic state scenarios,
for instance, by increasing the number of forces affecting the project’s value.
In Section 4, we illustrate the application of this model and methodology
using a simple numerical example applied to a pharmaceutical project. We also
perform a stress test analysis to determine the effects of certain economic forces600
on the overall project value and to determine the optimal time to launch a
project based on the interactions among these forces.
The model and methodology presented in this paper constitute a powerful
yet simple valuation instrument with strong practical applications for managers
and policy makers. As stated above, research-intensive industries are extremely605
complex and competitive. This context requires careful selection of projects.
When ranking projects, several forces, both economic and technical, driving the
drug development process that should be taken into account. In this regard, our
proposed model addresses forces playing significant roles in the project valuation
process in a very simple manner and provides a comprehensive tool for the610
decision-making process. The model and methodology proposed here can be
easily extrapolated to any other industry or corporate project.
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